Drug Approval | February 23, 2025
Briefs: Syngene International and Cipla
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
The inspection was successfully completed
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Subscribe To Our Newsletter & Stay Updated
